Epizyme, Inc.
Form 4
August 05, 2014

(Print or Type Responses)

| 1. Name and Address of Reporting Person * Rhodes Jason P |  |  | 2. Issuer Name and Ticker or Trading Symbol | 5. Relationship of Reporting Person(s) to Issuer |
| :---: | :---: | :---: | :---: | :---: |
|  | (First) | (Middle) | Epizyme, Inc. [EPZM] | (Check all applicable) |
| (Last) |  |  | 3. Date of Earliest Transaction (Month/Day/Year) |  |
| C/O EPIZ | INC. |  | 08/04/2014 | $\overline{\text { below) }} \mathrm{X}_{\text {- }}$ Officer (give title $\overline{\text { below) }}$ Other (specify |
| TECHN | SQU |  |  | President, CFO and Treasurer |
|  | (Street) |  | 4. If Amendment, Date Original | 6. Individual or Joint/Group Filing(Check |
|  |  |  | Filed(Month/Day/Year) | Applicable Line) |
| CAMBR | MA 0 |  |  | _X_ Form filed by One Reporting Person $\qquad$ Form filed by More than One Reporting Person |


value
(2)
$\$ 0.0001$
per share
Common
Stock, par \$
$\begin{array}{llllllll}\text { value } & \text { O8/04/2014 } & S_{-} & 18,400 & \mathrm{D} & 30.0488 & 82,000 & \mathrm{D}\end{array}$
\$0.0001
per share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

| Persons who respond to the collection of | SEC 1474 |
| :--- | ---: |
| information contained in this form are not | $(9-02)$ |
| required to respond unless the form |  |
| displays a currently valid OMB control |  |
| number. |  |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. <br> Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. <br> Transactio Code (Instr. 8) | 5. N <br> Deri <br> Secu <br> Acqu <br> or D <br> (D) <br> (Inst <br> and | mber of ative rities ired (A) sposed of $\text { . } 3,4 \text {, }$ | 6. Date Exercisable and Expiration Date (Month/Day/Year) |  | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Code V |  | (D) | Date <br> Exercisable | Expiration <br> Date | Title | Amount or Number of Shares |
| Stock <br> Option <br> (Right to Buy) | \$ 3.54 | 08/04/2014 |  | M [1) |  | 8,000 | (4) | 01/24/2023 | Common Stock | 8,000 |
| Stock <br> Option <br> (Right to <br> Buy) | \$ 0.6 | 08/04/2014 |  | $\mathrm{M} \underline{\text { (1) }}$ |  | 34,000 | (5) | 03/10/2021 | Common Stock | 34,000 |

## Reporting Owners

Reporting Owner Name / Address

## Relationships

Director $10 \%$ Owner Officer Other
Rhodes Jason P
C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE

President, CFO and Treasurer
CAMBRIDGE, MA 02139

## Signatures

/s/ Stephen Garbacz, attorney-in-fact

08/05/2014
**Signature of Reporting Person
Date

## Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. $78 \mathrm{ff}(\mathrm{a})$.
(1) The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $\$ 28.575$ per share to $\$ 29.55$ per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $\$ 29.61$
(3) per share to $\$ 30.49$ per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(4)

This option was granted on January 25, 2013 with respect to 310,833 shares of Common Stock, with $25 \%$ vesting on January 25, 2014 and the remaining $75 \%$ vesting in 36 substantially equal monthly installments thereafter.
(5) This option was granted on March 11, 2011 with respect to 108,819 shares of Common Stock, with $25 \%$ vesting on March 11, 2012 and the remaining $75 \%$ vesting in 36 substantially equal monthly installments thereafter.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

